Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC

This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of chidamide combined with benmelstobart, nab-paclitaxel, and immunogenic radiotherapy (SBRT) as second-line treatment in patients with advanced biliary tract cancer (BTC). The study plans to enroll 41 BTC patients who have previously received first-line systemic therapy, and these patients will receive chidamide, benmelstobart, nab-paclitaxel, and SBRT. The primary endpoint is progression-free survival (PFS), and the secondary endpoints include objective response rate (ORR), duration of response (DoR), overall survival (OS), and safety.